Evgeniia Prokhorova

Ms. Evgeniia Prokhorova

Sir William Dunn School of Pathology, University of Oxford
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2018 in eLife
Verified
Journal Article
Open access
LPLuca Palazzo
Luca Palazzo
OLOrsolya Leidecker
Orsolya Leidecker
EPEvgeniia Prokhorova
Evgeniia Prokhorova
HDHelen Dauben
Helen Dauben
IMIvan Matic
Ivan Matic
IAIvan Ahel
Ivan Ahel
Poly(ADP-ribose) polymerases (PARPs) are a family of enzymes that synthesise ADP-ribosylation (ADPr), a reversible modification of proteins that regulates many different cellular processes. Several mammalian PARPs are known to regulate the DNA damage response, but it is not clear which amino acids in proteins are the primary ADPr targets. Previously, we reported that ARH3 reverses the newly discovered type of ADPr (ADPr on serine residues; Ser-ADPr) and developed tools to analyse this modification (Fontana et al., 2017). Here, we show that Ser-ADPr represents the major fraction of ADPr synthesised after DNA damage in mammalian cells and that globally Ser-ADPr is dependent on HPF1, PARP1 and ARH3. In the absence of HPF1, glutamate/aspartate becomes the main target residues for ADPr. Furthermore, we describe a method for site-specific validation of serine ADP-ribosylated substrates in cells. Our study establishes serine as the primary form of ADPr in DNA damage signalling.

1 May 2017 in Trends in Cell Biology
Verified
Journal Article
Closed access
AZAlexey V. Zamaraev
Alexey V. Zamaraev
GKGelina S. Kopeina
Gelina S. Kopeina
EPEvgeniia Prokhorova
Evgeniia Prokhorova
BZBoris Zhivotovsky
Boris Zhivotovsky
Inna LavrikInna Lavrik
Inna Lavrik

1 September 2021 in DNA Repair
Verified
Journal Article
Open access
JGJoséphine Groslambert
Joséphine Groslambert
EPEvgeniia Prokhorova
Evgeniia Prokhorova
IAIvan Ahel
Ivan Ahel
ADP-ribosylation is a chemical modification of macromolecules found across all domains of life and known to regulate a variety of cellular processes. Notably, it has a well-established role in the DNA damage response. While it was historically known as a post-translational modification of proteins, recent studies have shown that nucleic acids can also serve as substrates of reversible ADP-ribosylation. More precisely, ADP-ribosylation of DNA bases, phosphorylated DNA ends and phosphorylated RNA ends have been reported. We will discuss these three types of modification in details. In a variety of bacterial species, including Mycobacterium tuberculosis, ADP-ribosylation of thymidine has emerged as the mode of action of a toxin-antitoxin system named DarTG, with the resultant products perceived as DNA damage by the cell. On the other hand, mammalian DNA damage sensors PARP1, PARP2 and PARP3 were shown to ADP-ribosylate phosphorylated ends of double-stranded DNA in vitro. Additionally, TRPT1 and several PARP enzymes, including PARP10, can add ADP-ribose to the 5'-phosphorylated end of single-stranded RNA in vitro, representing a novel RNA capping mechanism. Together, these discoveries have led to the emergence of a new and exciting research area, namely DNA and RNA ADP-ribosylation, that is likely to have far-reaching implications for the fields of DNA repair, replication and epigenetics.

7 September 2015 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
EPEvgeniia Prokhorova
Evgeniia Prokhorova
AZAlexey V. Zamaraev
Alexey V. Zamaraev
GKGelina S. Kopeina
Gelina S. Kopeina
BZBoris Zhivotovsky
Boris Zhivotovsky
ILInna N. Lavrik
Inna N. Lavrik

1 September 2018 in Cell Reports
Verified
Journal Article
Open access
EBEdward Bartlett
Edward Bartlett
JBJuan José Bonfiglio
Juan José Bonfiglio
EPEvgeniia Prokhorova
Evgeniia Prokhorova
TCThomas Colby
Thomas Colby
FZFlorian Zobel
Florian Zobel
IMIvan Matic
Ivan Matic
Serine ADP-ribosylation (Ser-ADPr) is a recently discovered protein modification that is catalyzed by PARP1 and PARP2 when in complex with the eponymous histone PARylation factor 1 (HPF1). In addition to numerous other targets, core histone tails are primary acceptors of Ser-ADPr in the DNA damage response. Here, we show that specific canonical histone marks interfere with Ser-ADPr of neighboring residues and vice versa. Most notably, acetylation, but not methylation of H3K9, is mutually exclusive with ADPr of H3S10 in vitro and in vivo. We also broaden the O-linked ADPr spectrum by providing evidence for tyrosine ADPr on HPF1 and other proteins. Finally, we facilitate wider investigations into the interplay of histone marks with Ser-ADPr by introducing a simple approach for profiling posttranslationally modified peptides. Our findings implicate Ser-ADPr as a dynamic addition to the complex interplay of modifications that shape the histone code.

1 June 2021 in Molecular Cell
Verified
Journal Article
Open access
EPEvgeniia Prokhorova
Evgeniia Prokhorova
TAThomas Agnew
Thomas Agnew
AWAnne R. Wondisford
Anne R. Wondisford
MTMichael Tellier
Michael Tellier
NKNicole Kaminski
Nicole Kaminski
IAIvan Ahel
Ivan Ahel
ARH3/ADPRHL2 and PARG are the primary enzymes reversing ADP-ribosylation in vertebrates, yet their functions in vivo remain unclear. ARH3 is the only hydrolase able to remove serine-linked mono(ADP-ribose) (MAR) but is much less efficient than PARG against poly(ADP-ribose) (PAR) chains in vitro. Here, by using ARH3-deficient cells, we demonstrate that endogenous MARylation persists on chromatin throughout the cell cycle, including mitosis, and is surprisingly well tolerated. Conversely, persistent PARylation is highly toxic and has distinct physiological effects, in particular on active transcription histone marks such as H3K9ac and H3K27ac. Furthermore, we reveal a synthetic lethal interaction between ARH3 and PARG and identify loss of ARH3 as a mechanism of PARP inhibitor resistance, both of which can be exploited in cancer therapy. Finally, we extend our findings to neurodegeneration, suggesting that patients with inherited ARH3 deficiency suffer from stress-induced pathogenic increase in PARylation that can be mitigated by PARP inhibition.